Telix Pharmaceuticals Archives

Radiotheranostics combines molecular imaging with targeted radioactive drugs, allowing clinicians to identify tumors carrying the therapeutic target before delivering systemic radiation treatment. Representative image.

What Telix’s EANM 2026 presentations reveal about its theranostics pipeline

by Pallavi Madhiraju
October 14, 2026
0 Comments

Telix will present 20 research abstracts at EANM 2026, including updates on pivotal brain and kidney cancer therapy trials, interim prostate cancer treatment findings and Phase 3 imaging data from China. The congress showcases a broad radiopharmaceutical pipeline, but most investigational programmes have not yet reported registrational efficacy results.

Brain tumour imaging advances as the US Food and Drug Administration approves Telix Pharmaceuticals’ PIXCLARA, the first FET-PET imaging agent to help distinguish glioma progression from treatment-related changes, improving precision in neuro-oncology diagnosis. Representative image.

Medical Devices & Diagnostics

Telix Pharmaceuticals wins FDA approval for PIXCLARA glioma imaging

by Pallavi Madhiraju
September 15, 2026
0 Comments

FDA approves Telix Pharmaceuticals’ PIXCLARA, the first FET-PET drug for differentiating glioma progression from treatment-related change.

Medical Devices & Diagnostics

Telix completes 350-patient Phase 3 BiPASS trial enrollment for PSMA-PET before prostate biopsy

by Pallavi Madhiraju
September 2, 2026
0 Comments

Telix has completed enrollment of 350 patients in the Phase 3 BiPASS study testing Illuccix and Gozellix PSMA-PET with MRI before prostate biopsy and has aligned with the FDA on an NDA pathway.